Patrick Wood
Stock Analyst at Morgan Stanley
(3.38)
# 1,000
Out of 4,732 analysts
74
Total ratings
48%
Success rate
6.16%
Average return
Main Sectors:
Stocks Rated by Patrick Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Maintains: Equal-Weight | $104 → $102 | $93.27 | +9.36% | 5 | Dec 6, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Overweight | $45 | $35.15 | +28.02% | 3 | Dec 2, 2024 | |
| GKOS Glaukos | Downgrades: Underweight | $120 | $156.39 | -23.27% | 3 | Dec 2, 2024 | |
| BLCO Bausch + Lomb | Downgrades: Equal-Weight | $19 | $17.36 | +9.45% | 6 | Dec 2, 2024 | |
| PRCT PROCEPT BioRobotics | Initiates: Overweight | $105 | $76.02 | +38.12% | 1 | Dec 2, 2024 | |
| SOLV Solventum | Maintains: Equal-Weight | $60 → $73 | $73.51 | -0.69% | 3 | Nov 11, 2024 | |
| PODD Insulet | Maintains: Overweight | $234 → $317 | $275.81 | +14.93% | 5 | Nov 11, 2024 | |
| BSX Boston Scientific | Maintains: Overweight | $92 → $100 | $98.66 | +1.36% | 4 | Oct 24, 2024 | |
| EW Edwards Lifesciences | Reinstates: Equal-Weight | $70 | $69.78 | +0.32% | 7 | Oct 11, 2024 | |
| DXCM DexCom | Maintains: Equal-Weight | $120 → $75 | $84.38 | -11.12% | 6 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $10 | $15.85 | -36.91% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $104 → $145 | $57.20 | +153.50% | 1 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $65 → $85 | $84.37 | +0.75% | 3 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $37 | $22.29 | +65.99% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $39 → $30 | $30.98 | -3.16% | 3 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $74 → $86 | $84.74 | +1.49% | 5 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $225 → $215 | $209.62 | +2.57% | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $310 → $280 | $237.38 | +17.95% | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $181.27 | - | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $30.39 | +18.46% | 1 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $166.24 | - | 5 | Dec 11, 2017 |
The Cooper Companies
Dec 6, 2024
Maintains: Equal-Weight
Price Target: $104 → $102
Current: $93.27
Upside: +9.36%
Tandem Diabetes Care
Dec 2, 2024
Upgrades: Overweight
Price Target: $45
Current: $35.15
Upside: +28.02%
Glaukos
Dec 2, 2024
Downgrades: Underweight
Price Target: $120
Current: $156.39
Upside: -23.27%
Bausch + Lomb
Dec 2, 2024
Downgrades: Equal-Weight
Price Target: $19
Current: $17.36
Upside: +9.45%
PROCEPT BioRobotics
Dec 2, 2024
Initiates: Overweight
Price Target: $105
Current: $76.02
Upside: +38.12%
Solventum
Nov 11, 2024
Maintains: Equal-Weight
Price Target: $60 → $73
Current: $73.51
Upside: -0.69%
Insulet
Nov 11, 2024
Maintains: Overweight
Price Target: $234 → $317
Current: $275.81
Upside: +14.93%
Boston Scientific
Oct 24, 2024
Maintains: Overweight
Price Target: $92 → $100
Current: $98.66
Upside: +1.36%
Edwards Lifesciences
Oct 11, 2024
Reinstates: Equal-Weight
Price Target: $70
Current: $69.78
Upside: +0.32%
DexCom
Jul 26, 2024
Maintains: Equal-Weight
Price Target: $120 → $75
Current: $84.38
Upside: -11.12%
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $18 → $10
Current: $15.85
Upside: -36.91%
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $104 → $145
Current: $57.20
Upside: +153.50%
Jul 15, 2024
Upgrades: Equal-Weight
Price Target: $65 → $85
Current: $84.37
Upside: +0.75%
Jul 15, 2024
Downgrades: Underweight
Price Target: $50 → $37
Current: $22.29
Upside: +65.99%
Jul 15, 2024
Downgrades: Underweight
Price Target: $39 → $30
Current: $30.98
Upside: -3.16%
Feb 12, 2024
Maintains: Equal-Weight
Price Target: $74 → $86
Current: $84.74
Upside: +1.49%
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $225 → $215
Current: $209.62
Upside: +2.57%
Dec 4, 2023
Maintains: Overweight
Price Target: $310 → $280
Current: $237.38
Upside: +17.95%
Dec 4, 2023
Upgrades: Overweight
Price Target: n/a
Current: $181.27
Upside: -
Dec 4, 2023
Initiates: Overweight
Price Target: $36
Current: $30.39
Upside: +18.46%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $166.24
Upside: -